Asthma Management in CHildren Based on Exhaled Nitric Oxide - Randomised Controlled Trial
Not yet recruiting
- Conditions
- AsthmaRespiratory - Asthma
- Registration Number
- ACTRN12605000321640
- Lead Sponsor
- Royal Children's Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Children with asthma attending a paediatric specialist clinic.
Exclusion Criteria
Presence of other cardiorespiratory illness such as CF, trachemalacia, etc.Poorly compliant to treatment.Inability to take ICS or long acting beta-2-antagonists (LABA).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduced asthma exacerbations during 12 months[];Reduced asthma hospitalisations during 12 months[]
- Secondary Outcome Measures
Name Time Method Cough and asthma score[Completed daily for a duration of 12 months.];Child QOL and carer/parent QOL[Administered monthly for 4 months and then second monthly for 8 months. ]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link exhaled nitric oxide (FeNO) levels to asthma exacerbation risk in children?
How does FeNO-guided asthma management compare to standard-of-care in reducing pediatric exacerbations?
Which biomarkers predict response to FeNO-targeted interventions in eosinophilic asthma subtypes?
What adverse events are associated with FeNO-based inhaled corticosteroid adjustments in pediatric trials?
What combination therapies or alternative biomarkers (e.g., sputum eosinophils) are being explored alongside FeNO for asthma management?